Hypertrophic Cardiomyopathy (HCM) Latest Advances

Find the Latest Research About Hypertrophic Cardiomyopathy (HCM)

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22718 publications

FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis.

FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis.

Journal: Circulation. Genomic and precision medicine
Published: April 14, 2026

Cardiology: What You May Have Missed in 2025.

Cardiology: What You May Have Missed in 2025.

Journal: Annals of internal medicine
Published: April 13, 2026

Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.

Mavacamten Versus Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: An Echocardiography-Derived Pressure-Volume Analysis.

Journal: Circulation. Heart failure
Published: April 13, 2026

RoMa: A Cardiopulmonary Exercise Testing Based Risk Tool in Hypertrophic Cardiomyopathy.

RoMa: A Cardiopulmonary Exercise Testing Based Risk Tool in Hypertrophic Cardiomyopathy.

Journal: Journal of the American Heart Association
Published: April 09, 2026

RoMa Classification: When the Parts Do Not Equal the Sum.

RoMa Classification: When the Parts Do Not Equal the Sum.

Journal: Journal of the American Heart Association
Published: April 09, 2026

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal: European heart journal
Published: April 08, 2026

Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy.

Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy.

Journal: Journal of Cardiac Failure. Intersections
Published: April 08, 2026

Concerns Regarding the Interpretation of Triglyceride-Glucose Index as a Protective Factor in Hypertrophic Cardiomyopathy.

Concerns Regarding the Interpretation of Triglyceride-Glucose Index as a Protective Factor in Hypertrophic Cardiomyopathy.

Journal: Anatolian journal of cardiology
Published: April 07, 2026

Emerging treatments in hypertrophic cardiomyopathy: a focus on cardiac myosin inhibitors.

Emerging treatments in hypertrophic cardiomyopathy: a focus on cardiac myosin inhibitors.

Journal: Expert opinion on pharmacotherapy
Published: April 06, 2026

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal: Journal of the American College of Cardiology
Published: April 06, 2026

From Risk Scores to Precision Cardiology: Redefining Sudden Cardiac Death Prediction in Hypertrophic Cardiomyopathy.

From Risk Scores to Precision Cardiology: Redefining Sudden Cardiac Death Prediction in Hypertrophic Cardiomyopathy.

Journal: European heart journal. Cardiovascular Imaging
Published: April 02, 2026

IMPORTANCE OF THE SURGICAL MYECTOMY OPTION IN THE CHANGING LANDSCAPE OF MANAGEMENT FOR SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY.

IMPORTANCE OF THE SURGICAL MYECTOMY OPTION IN THE CHANGING LANDSCAPE OF MANAGEMENT FOR SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY.

Journal: Trends in cardiovascular medicine
Published: April 02, 2026
Showing 1-12 of 22,718

Last Updated: 04/28/2026